Daniel S. Lorrain sold $595k of CTNM
Chief Scientific Officer at Contineum Therapeutics, Inc.. 37,179 shares at an average of $15.99, traded Jun 30, 2026, filed Jul 2, 2026.
Score components
- +15RoleOfficer
- +19Trade size$595k at market
- +5Share of holdings soldSold 22% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001628280-26-047058, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 30, 2026 | MOption exercise Class A Common Stock10b5-1 | +28,826 | $1.01 | $29k | 168,198 | Jul 2, 2026 |
| Jun 30, 2026 | SOpen-market sale Class A Common Stock10b5-1 | -28,826 | $16.04 | $462k | 139,372 | Jul 2, 2026 |
| Jul 1, 2026 | MOption exercise Class A Common Stock10b5-1 | +4,183 | $1.01 | $4,225 | 143,555 | Jul 2, 2026 |
| Jul 1, 2026 | SOpen-market sale Class A Common Stock10b5-1 | -5,852 | $15.67 | $92k | 137,703 | Jul 2, 2026 |
| Jul 1, 2026 | SOpen-market sale Class A Common Stock10b5-1 | -2,501 | $16.24 | $41k | 135,202 | Jul 2, 2026 |
| Jun 30, 2026 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -28,826 | $0.00 | $0 | 38,480 | Jul 2, 2026 |
| Jul 1, 2026 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -4,183 | $0.00 | $0 | 34,297 | Jul 2, 2026 |
Related signals
Other insiders at Contineum Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 1Weak | Contineum Therapeutics, Inc. | Carmine N. Stengone CEO and President | $41k 2,500 shares | -13% | |
| 1Weak | Contineum Therapeutics, Inc. | Carmine N. Stengone CEO and President | $40k 2,500 shares | -13% | |
| 0Weak | Contineum Therapeutics, Inc. | Daniel S. Lorrain Chief Scientific Officer | $17k 1,040 shares | -1% | |
| 16Weak | Contineum Therapeutics, Inc. | Carmine N. Stengone CEO and President | $40k 2,500 shares | -13% | |
| 26Weak | Contineum Therapeutics, Inc. | Carmine N. Stengone CEO and President | $160k 10,000 shares | -37% | |
| 26Weak | Contineum Therapeutics, Inc. | Tim Watkins CMO & Head of Development | $174k 10,833 shares | -55% | |
| 2Weak | Contineum Therapeutics, Inc. | Daniel S. Lorrain Chief Scientific Officer | $55k 4,170 shares | -3% | |
| 2Weak | Contineum Therapeutics, Inc. | Daniel S. Lorrain Chief Scientific Officer | $55k 4,170 shares | -3% | |
| 2Weak | Contineum Therapeutics, Inc. | Daniel S. Lorrain Chief Scientific Officer | $56k 4,170 shares | -3% | |
| 22Weak | Contineum Therapeutics, Inc. | Tim Watkins CMO & Head of Development | $54k 3,611 shares | -100% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.